Get the Stockscreener App
44.77
0.38%
0.17
Pre-market:
44.91
0.14
+0.31%
Sanofi Adr stock is traded at $44.77, with a volume of 3.15M.
It is up +0.38% in the last 24 hours and down -5.19% over the past month.
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for over 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.
See More
Previous Close:
$44.60
Open:
$44.86
24h Volume:
3.15M
Relative Volume:
0.79
Market Cap:
$107.72B
Revenue:
$49.41B
Net Income/Loss:
$5.59B
P/E Ratio:
18.75
EPS:
2.3875
Net Cash Flow:
$8.32B
1W Performance:
+1.80%
1M Performance:
-5.19%
6M Performance:
-4.50%
1Y Performance:
-21.32%
1-Day Range:
$44.49
$45.26
1-Week Range:
$43.32
$45.52
52-Week Range:
$43.32
$56.93
Sanofi Adr Stock (SNY) Company Profile
Name
Sanofi Adr
Sector
Industry
Phone
-
Address
-
Compare SNY vs LLY, JNJ, ABBV, MRK, AZN
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SNY
Sanofi Adr
|
44.77 | 107.72B | 49.41B | 5.59B | 8.32B | 2.3875 |
LLY
Lilly Eli Co
|
910.55 | 813.11B | 65.18B | 20.64B | 5.96B | 22.59 |
JNJ
Johnson Johnson
|
235.42 | 567.04B | 94.19B | 26.80B | 19.70B | 11.05 |
ABBV
Abbvie Inc
|
204.93 | 362.35B | 61.16B | 4.19B | 17.82B | 2.3614 |
MRK
Merck Co Inc
|
115.68 | 286.01B | 64.93B | 18.26B | 12.36B | 7.2751 |
AZN
Astrazeneca Plc
|
184.07 | 285.46B | 58.80B | 10.24B | 8.98B | 3.2788 |
Sanofi Adr Stock (SNY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-12-26 | Downgrade | BofA Securities | Buy → Neutral |
| Jan-27-26 | Initiated | Citigroup | Neutral |
| Jan-16-26 | Downgrade | UBS | Buy → Neutral |
| Jan-06-26 | Downgrade | Barclays | Overweight → Equal Weight |
| Dec-09-25 | Downgrade | Guggenheim | Buy → Neutral |
| Dec-08-25 | Downgrade | JP Morgan | Overweight → Neutral |
| Sep-08-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Sep-02-25 | Upgrade | Deutsche Bank | Hold → Buy |
| Aug-08-25 | Upgrade | JP Morgan | Neutral → Overweight |
| Apr-15-25 | Initiated | Exane BNP Paribas | Outperform |
| Mar-21-25 | Initiated | Goldman | Neutral |
| Jan-30-25 | Upgrade | Deutsche Bank | Sell → Hold |
| Jul-26-24 | Reiterated | Argus | Buy |
| Jan-23-24 | Initiated | Morgan Stanley | Equal-Weight |
| Jan-16-24 | Resumed | UBS | Buy |
| Dec-05-23 | Downgrade | JP Morgan | Overweight → Neutral |
| Oct-30-23 | Downgrade | Stifel | Buy → Hold |
| Sep-06-23 | Upgrade | Berenberg | Hold → Buy |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Apr-28-23 | Downgrade | Deutsche Bank | Hold → Sell |
| Mar-27-23 | Upgrade | Barclays | Equal Weight → Overweight |
| Dec-13-22 | Resumed | Morgan Stanley | Overweight |
| Aug-12-22 | Upgrade | Deutsche Bank | Sell → Hold |
| Aug-09-22 | Downgrade | UBS | Buy → Neutral |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Sep-27-21 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Jan-15-21 | Initiated | Deutsche Bank | Sell |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Mar-17-20 | Upgrade | Barclays | Underweight → Equal Weight |
| Mar-11-20 | Upgrade | Goldman | Neutral → Buy |
| Feb-11-20 | Initiated | SVB Leerink | Mkt Perform |
| Jan-06-20 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-23-19 | Upgrade | Guggenheim | Neutral → Buy |
| Sep-20-19 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Sep-03-19 | Initiated | Bernstein | Outperform |
| Aug-14-19 | Upgrade | UBS | Neutral → Buy |
| Dec-11-18 | Upgrade | Jefferies | Hold → Buy |
| Nov-01-18 | Upgrade | Barclays | Underweight → Equal Weight |
| Oct-09-18 | Initiated | Guggenheim | Neutral |
| Sep-10-18 | Upgrade | BofA/Merrill | Neutral → Buy |
| Aug-10-18 | Upgrade | Citigroup | Neutral → Buy |
| Mar-23-18 | Upgrade | Liberum | Hold → Buy |
| Jan-23-18 | Downgrade | Barclays | Equal Weight → Underweight |
| Dec-06-17 | Downgrade | BofA/Merrill | Buy → Neutral |
| Dec-01-17 | Downgrade | Morgan Stanley | Overweight → Underweight |
| Nov-15-17 | Upgrade | Barclays | Underweight → Equal Weight |
| Aug-30-17 | Upgrade | HSBC Securities | Reduce → Hold |
View All
Sanofi Adr Stock (SNY) Latest News
Communiqué de presse : Dupixent, développé par Sanofi et Regeneron, a été approuvé au Japon comme premier médicament ciblé pour le traitement des adultes atteints de pemphigoïde bulleuse - GlobeNewswire Inc.
Medicare Chief Chris Klomp Optimistic On CDC Director Search As Vaccine Fight Roils Agency— 'We Will Select...' - Sahm
Federal Judge Flags Legal Flaws In RFK Jr.'s Vaccine Overhaul - Sahm
SNY Stock Price, Quote & Chart | SANOFI-ADR (NASDAQ:SNY) - ChartMill
Dupixent Leads the Charge for Sanofi's Strong Portfolio in Immunology, Vaccines, and Rare Diseases - Morningstar
MRNA Stock Gains After CHMP Endorses COVID-19-Influenza Combo Shot - Finviz
Antibiotics Market - GlobeNewswire Inc.
Sanofi (SNY) and Regeneron's Dupixent Recommended for EU Approval - Finviz
Kymera Q4 Loss Wider Than Expected, Cash Boost Extends Runway - Finviz
DNLI Q4 Loss Narrower Than Expected, Hunter Syndrome Drug in Focus - Finviz
Novavax Stock Gains as Q4 Earnings & Sales Beat Estimates - Finviz
How Do Investors Really Feel About Sanofi SA? - Sahm
CYTK Posts a Wider-Than-Expected Q4 Loss, Advances Myqorzo Launch Plans - Finviz
BMRN Beats on Q4 Earnings, to Withdraw Roctavian From Market - Finviz
Sanofi's (SNY) R&D Track Record Remains Investor Concern, Says BofA - Finviz
Manuela Buxo To Become Head of Sanofi's (SNY) Specialty Care Global Business Unit - Finviz
Teva And Sanofi Duvakitug Data Support IBD Pipeline And Growth Story - Sahm
Teva and Sanofi’s duvakitug phase 2b maintenance data demonstrated clinically meaningful durable efficacy in ulcerative colitis and Crohn’s disease - Sahm
RIGL Stock Rises 59% in a Year: Time to Buy, Hold or Sell? - Finviz
SNY Stock Falls After Board Suddenly Makes Leadership Change - Finviz
Sanofi Pulls the Emergency Brake: What the Hudson Ouster and Garijo Appointment Really Mean for Investors - CTOL Digital Solutions
Should Investors Buy, Sell or Hold Amicus Stock Ahead of Q4 Earnings? - Finviz
SNY's Rare Disease Drug Wins FDA Breakthrough and Japan Orphan Status - Finviz
Sanofi (SNY) Strengthens Shareholder Returns Amid Robust 2025 Performance and Long-Term Growth Outlook - Finviz
Is Sanofi SA (SNY) One of the Best Cheap Stocks to Buy for 2026 - Finviz
Sanofi Found In Breach Of UK Pharmaceutical Marketing Code Over Beyfortus Claims - Sahm
FedEx Upgraded, Costco Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
Sanofi Plans Regulatory Submission For Investigational Drug For Rare Disease Despite Mixed Data From Pivotal Trials - Sahm
Analysts Have Conflicting Sentiments on These Healthcare Companies: Regeneron (REGN), Resmed (RMD) and Sanofi (OtherSNYNF) - The Globe and Mail
REGN Q4 Earnings Beat Estimates, Sales Rise on Eylea HD Growth - Finviz
European ADRs Slip, But Still End The Week Higher - Finimize
Sanofi ADR earnings beat by $0.69, revenue fell short of estimates - Investing.com South Africa
SNY Stock Today: January 30 RSV Wave in Germany Puts Beyfortus in Focus - Meyka
TEVA's Q4 Earnings Beat, Branded Drugs Drive Revenue Growth - Finviz
Earnings call transcript: Sanofi Q4 2025 earnings beat EPS forecast - Investing.com
Earnings Preview: Sanofi - Sahm
Sanofi Adr Stock (SNY) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.74%
0.79%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):